Clinical Trial Detail

NCT ID NCT03092674
Title Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

acute myeloid leukemia

myelodysplastic syndrome

Therapies

Cytarabine + Decitabine

Azacitidine + Midostaurin

Azacitidine + Nivolumab

Azacitidine

Age Groups: senior adult

No variant requirements are available.